1.
|
Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MKC-102, NCT00408226
|
|
2.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-00139, ROCHE-16113, ROCHE-RO31-7453, NCI-G01-1945, NCT00016250
|
|
3.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MKC-101, NCT00306631
|
|
4.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MKC-105, NCT00568646
|
|
5.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MKC-103, NCT00607607
|
|
6.
|
Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-98099, ROCHE-NO15857A, NCI-G99-1499, NCT00003755
|
|
7.
|
Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-00118, ROCHE-NP15980C, NCI-G01-1928, NCT00014365
|
|
8.
|
Phase: Phase I Type: Treatment Status: Completed Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: MKC-104, NCT00506402
|
|
9.
|
Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MKC-106, NCT00656461
|